Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2025-12-26 @ 3:19 AM
Study NCT ID:
NCT05799820
Status:
UNKNOWN
Last Update Posted:
2023-05-25
First Post:
2023-03-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Sponsor:
Qilu Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-29
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-03-23
First Submit QC Date:
None
Study First Post Date:
2023-04-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-23
Last Update Post Date:
2023-05-25
Last Update Post Date Type:
ACTUAL